Nuvalent is currently navigating a critical transition into late-stage clinical development, characterized by a sharp escalation in R&D spending to support its lead assets, NVL-520 and NVL-655. While the company maintains a robust equity base of $1.2 billion, ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
The company remains in a pre-revenue stage with operating losses widening to $119.4 million in 2026Q1, driven by a surge in R&D expenditures from $35.6 million in 2023Q4 to $83.6 million.
Nuvalent has a strong cash position, providing financial stability and flexibility to advance its pipeline.
The company's pipeline includes promising cancer drugs like zidesamtinib, neladalkib, and NVL-330, offering high-risk, high-reward potential.
Neladalkib has shown durable responses, which could drive significant commercial success in treating targeted cancers.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 7, 2026 | -$1.39-3.0% vs -$1.35 | — vs $486,000 |
Q1 2026 Feb 26, 2026 | -$1.29+12.8% vs -$1.48 | — vs $7M |
Q4 2025 Oct 30, 2025 | -$1.70-22.3% vs -$1.39 | — vs — |
Q3 2025 Aug 7, 2025 | -$1.31-3.1% vs -$1.27 | — vs — |
Fifth Third Bancorp bought a new position in shares of Nuvalent, Inc. (NASDAQ: NUVL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 23,621 shares of the company's stock, valued at approximately $2,420,000. Other institutional investors and hedge funds
Benchmark NUVL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nuvalent, Inc. (NUVL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $123.96 | $9.13B | -21.19 | — | — | -36.7% | — | |
| $11.63 | $372.14M | 5.06 | 6774.96% | -553.88% | -21.4% | — | |
| $0.92 | $14.04M | -0.15 | — | — | -1270.11% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $13.95 | $4.84B | -31.69 | — | — | -80.43% | — | |
| $74.29 | $3.2B | -46.72 | 146.71% | -7.67% | -13.53% | — |
Nuvalent, Inc. (NUVL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nuvalent, Inc. (NUVL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 15, 2026·SEC
Jun 18, 2026·SEC
Jun 9, 2026·SEC
Get notified when NUVL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nuvalent, Inc. (NUVL) stock FAQ — growth, dividends, profitability & financials explained
Nuvalent, Inc. (NUVL) reported a net loss of $450.1M for fiscal year 2025.
Nuvalent, Inc. (NUVL) has a return on equity (ROE) of -36.7%. Negative ROE indicates the company is unprofitable.
Nuvalent, Inc. (NUVL) had negative free cash flow of $312.8M in fiscal year 2025, likely due to heavy capital investments.
